BPC-157 Legal Status, FDA 503A Category, and Compounding Access

Why the BPC-157 legal status is worth reading carefully right now

The BPC-157 legal status is in motion, and the forward-leaning fact is real: BPC-157 is individually named on the published agenda of the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23-24, 2026, as a bulk drug substance "being considered for inclusion on the 503A Bulks List" (the same agenda also lists KPV, TB-500, and MOTs-C) ^[16]. Access to compounded BPC-157 is, in that precise sense, under active FDA review and may expand in 2026.

That momentum is worth stating plainly — and it is equally important to be exact about what it is not. A PCAC agenda item is a scheduled evaluation and discussion only. It is not a listing decision, not a reclassification, and not a change in the substance's current status ^[16]. The committee is advisory; inclusion on a final 503A bulks list is decided by FDA rulemaking, informed by — but not bound by — PCAC ^[13]. So the right reading of mid-2026 is: a named substance, on the agenda, under evaluation, with no outcome assumed, stated, or dated ^[16].

The current FDA fact, stated present-tense

As of now, BPC-157 — FDA evaluated the list entries "BPC-157 (free base)" and "BPC-157 acetate" — is a research peptide that FDA placed in 503A "Category 2," the category of bulk substances FDA has identified as potentially presenting significant safety risks ^[14]. The placement is effective with FDA's September 29, 2023 update to the list of bulk drug substances nominated for use under section 503A ^[14]. FDA's stated rationale includes concerns about potential immunogenicity for certain routes of administration and complexities with peptide-related impurities and active-ingredient characterization ^[14].

Two consequences follow directly. First, as a Category 2 substance, BPC-157 is not covered by FDA's enforcement-discretion policy for 503A compounding — the policy that applies to Category 1 substances does not extend to it ^[13][14]. Second, BPC-157 is not an FDA-approved drug; approval of a finished drug is a separate question from whether a bulk substance may be used in compounding, and BPC-157 has neither status ^[13].

How the 503A and 503B framework works

Under the U.S. Federal Food, Drug, and Cosmetic Act, two sections govern compounding. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered "outsourcing facilities" that compound larger batches under cGMP-style oversight ^[13].

A compounder may use a bulk drug substance only if that substance has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulks list; substances not yet on a list are evaluated by FDA through a public nomination process with PCAC input ^[13]. FDA's interim policy sorted nominated substances into Category 1 (covered by enforcement discretion while under evaluation) and Category 2 (identified as raising significant safety risks; not covered). On January 7, 2025, FDA finalized a revised interim policy under which it no longer places newly nominated substances into these numbered categories; substances already in Category 2 are not afforded that discretion even if nominations are updated ^[13][15]. Against that backdrop, BPC-157 remains in Category 2 — the last FDA action confirmable from FDA.gov ^[14].

What this means for compounded access

How does legally compounded peptide access work in general? A patient is first evaluated by an appropriately licensed prescriber — in person or through a compliant telehealth encounter — who determines whether a compounded preparation is clinically appropriate ^[13]. If it is appropriate and lawful, the prescriber issues a valid, patient-specific prescription. That prescription is then dispensed by a state-licensed 503A compounding pharmacy, or, for office or batch use, sourced from an FDA-registered 503B outsourcing facility ^[13].

Telehealth, where used, is simply the front-end channel for that prescriber-evaluation step; it does not change which substances are eligible to be compounded, and it does not remove the need for a legitimate clinical relationship and a valid prescription ^[13]. The decisive caveat sits at the ingredient: a compounded preparation may lawfully be made only when its active ingredient is eligible under the 503A/503B framework, and a substance FDA has flagged for significant safety risks is not eligible for routine 503A compounding while that status stands ^[13]. For BPC-157, that is the operative constraint today ^[14]. This page names no specific pharmacy, clinic, telehealth provider, or vendor, gives no dosing, and describes no way to obtain a restricted substance outside the lawful framework — it is general information, not medical or legal advice, and not an offer to sell or supply anything.

Is BPC-157 legal?

BPC-157 is not an FDA-approved drug, and FDA placed it in 503A Category 2 — bulk substances identified as potentially presenting significant safety risks — effective with its September 29, 2023 update ^[14]. It is also prohibited in sport at all times by the World Anti-Doping Agency under the non-approved-substances category. Legality depends on jurisdiction and use-context; this page describes the U.S. compounding-regulatory landscape, not a blanket legal verdict.

Can you get BPC-157 from a compounding pharmacy?

Not through routine 503A compounding while its current status stands. In its September 29, 2023 update, FDA placed BPC-157 in Category 2, which sits outside FDA's enforcement-discretion policy for 503A compounding ^[14]. A Category 2 substance is not eligible for routine 503A compounding, so a licensed prescriber's evaluation alone does not make the ingredient eligible ^[13]. BPC-157 is, however, scheduled for PCAC discussion in July 2026 as a candidate for the bulks list — an evaluation, not a decision ^[16].

What is the FDA 503A status of BPC-157?

BPC-157 was identified by FDA as a bulk drug substance placed in 503A Category 2 — potentially presenting significant safety risks — effective with its September 29, 2023 nominated-substances update, and it is therefore not within FDA's enforcement-discretion policy for 503A compounding ^[14]. The entries FDA evaluated are "BPC-157 (free base)" and "BPC-157 acetate" ^[14]. BPC-157 is on the published agenda of the July 23-24, 2026 PCAC meeting as a substance being considered for the 503A Bulks List, which is a scheduled discussion and not a listing decision or a reclassification ^[16].